Mark J. Ratain

37.9k total citations · 10 hit papers
532 papers, 23.0k citations indexed

About

Mark J. Ratain is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark J. Ratain has authored 532 papers receiving a total of 23.0k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Oncology, 205 papers in Molecular Biology and 95 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark J. Ratain's work include Cancer therapeutics and mechanisms (108 papers), Cancer Treatment and Pharmacology (93 papers) and Pharmacogenetics and Drug Metabolism (84 papers). Mark J. Ratain is often cited by papers focused on Cancer therapeutics and mechanisms (108 papers), Cancer Treatment and Pharmacology (93 papers) and Pharmacogenetics and Drug Metabolism (84 papers). Mark J. Ratain collaborates with scholars based in United States, Japan and China. Mark J. Ratain's co-authors include Federico Innocenti, Jacqueline Ramı́rez, Richard L. Schilsky, Lalitha Iyer, Walter M. Stadler, Linda Janisch, Lillian L. Siu, Philippe L. Bédard, Aaron R. Hansen and Soma Das and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Mark J. Ratain

520 papers receiving 22.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour heterogeneity in the clinic

2013 897 citations Mark J. Ratain et al. profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

2004 695 citations Federico Innocenti, Samir D. Undevia et al. Journal of Clinical Oncology profile →
Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

2016 585 citations Mark J. Ratain, Christopher K. Daugherty et al. profile →
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

1998 541 citations Mark J. Ratain et al. profile →
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

2002 521 citations Soma Das, Linda Janisch et al. The Pharmacogenomics Journal profile →
The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

2014 445 citations Mark J. Ratain, Christopher K. Daugherty et al. profile →
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

2011 445 citations Ezra E.W. Cohen, Linda Janisch et al. Journal of Clinical Oncology profile →
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

2018 434 citations Theodore Karrison, Yuanyuan Zha et al. Journal of Clinical Oncology profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

2018 237 citations Howard L. McLeod, Mark J. Ratain et al. profile →

Peers

Countries citing papers authored by Mark J. Ratain

Since Specialization

Citations

This map shows the geographic impact of Mark J. Ratain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Ratain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Ratain more than expected).

Fields of papers citing papers by Mark J. Ratain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Ratain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Ratain. The network helps show where Mark J. Ratain may publish in the future.

Co-authorship network of co-authors of Mark J. Ratain

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Ratain. A scholar is included among the top collaborators of Mark J. Ratain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Ratain. Mark J. Ratain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance) 2024 ·The Pharmacogenomics Journal ·Jai N. Patel, Chen Jiang, Kouros Owzar, Daniel L. Hertz, Janey Wang, Flora Mulkey, William Kevin Kelly, Susan Halabi, Yoichi Furukawa, (unknown), Susan G. Dorsey, Paula N. Friedman, Eric J. Small, Michael A. Carducci, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Mark J. Ratain, Michael J. Morris, Howard L. McLeod	0
2	Negative innovation: when patents are bad for patients 2021 ·Nature Biotechnology ·Robin Feldman, David A. Hyman, W. Nicholson Price, Mark J. Ratain	8
3	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) 2020 ·Clinical Cancer Research ·Federico Innocenti, Alexander B. Sibley, (unknown), Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou, (unknown), Sarah J. Plummer, Graham Casey, Monica M. Bertagnolli, Howard L. McLeod, J. Todd Auman, Charles D. Blanke, Yoichi Furukawa, Alan P. Venook, Michiaki Kubo, Heinz‐Josef Lenz, Joel S. Parker, Mark J. Ratain, Kouros Owzar	13
4	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients 2020 ·The AAPS Journal ·(unknown), Amy S. Etheridge, Eleftheria Tsakalozou, Jacqueline Ramı́rez, Erika Cecchin, Ron H. N. van Schaik, Giuseppe Toffoli, Mark J. Ratain, Ron H.J. Mathijssen, Alan Forrest, Robert R. Bies, Federico Innocenti	4
5	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide 2015 ·Clinical Cancer Research ·Peter H. O’Donnell, (unknown), Theodore Karrison, Linda Janisch, (unknown), Pamela Jo Harris, Blasé N. Polite, Ezra E.W. Cohen, Gini F. Fleming, Mark J. Ratain, Michael L. Maitland	4
6	UGT1A and UGT2B Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Catherine A. Wassenaar, David V. Conti, Soma Das, Peixian Chen, Edwin H. Cook, Mark J. Ratain, Neal L. Benowitz, Rachel F. Tyndale	25
7	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies 2014 ·Clinical Cancer Research ·Ravi Salgia, Premal H. Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Catenacci, Amy Peterson, Mark J. Ratain, Blasé N. Polite, Janice M. Mehnert, Rebecca A. Moss	56
8	Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study 2013 ·Clinical Cancer Research ·Jiping Wang, Luis G. Carvajal‐Carmona, J Chu, Ann G. Zauber, (unknown), (unknown), Koichi Matsuda, Malcolm G. Dunlop, Richard S. Houlston, Oliver M. Sieber, Lara Lipton, Peter Gibbs, Nicholas G. Martin, Grant W. Montgomery, Joanne Young, Paul N. Baird, Mark J. Ratain, Yusuke Nakamura, Scott T. Weiss, Ian Tomlinson, Monica M. Bertagnolli	8
9	Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs 2013 ·Clinical Cancer Research ·Kehua Wu, Larry House, Jacqueline Ramı́rez, Michael J. Seminerio, Mark J. Ratain	5
10	Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy 2012 ·Clinical Cancer Research ·Heather E. Wheeler, Eric R. Gamazon, Claudia Wing, (unknown), (unknown), R. Michael Baldwin, Kouros Owzar, Chen Jiang, Dorothy Watson, Ivo Shterev, Michiaki Kubo, Hitoshi Zembutsu, Eric P. Winer, Clifford A. Hudis, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, Deanna L. Kroetz, Nancy J. Cox, (unknown)	49
11	Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints 2012 ·Clinical Cancer Research ·Manish Sharma, Theodore Karrison, Yuyan Jin, Robert R. Bies, Michael L. Maitland, Walter M. Stadler, Mark J. Ratain	23
12	Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients 2012 ·Clinical Cancer Research ·Ezra E.W. Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, (unknown), Yuanyuan Zha, (unknown), Michael L. Maitland, (unknown), (unknown), Larry House, Jacqueline Ramı́rez, Samir D. Undevia, Gini F. Fleming, Thomas F. Gajewski, Mark J. Ratain	51
13	A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 2012 ·Clinical Cancer Research ·R. Michael Baldwin, Kouros Owzar, Hitoshi Zembutsu, Aparna Chhibber, Michiaki Kubo, Chen Jiang, Dorothy Watson, (unknown), Joel Mefford, Howard L. McLeod, Paula N. Friedman, Clifford A. Hudis, Eric P. Winer, Eric Jorgenson, John S. Witte, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, Deanna L. Kroetz	160
14	Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions 2011 ·Cancer Research ·Wanqing Liu, Lijun He, Jacqueline Ramı́rez, Soundararajan Krishnaswamy, Rajani Kanteti, Yi‐Ching Wang, Ravi Salgia, Mark J. Ratain	36
15	Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells 2009 ·Clinical Cancer Research ·Wanqing Liu, Lijun He, Jacqueline Ramı́rez, Mark J. Ratain	15
16	Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment 2009 ·Clinical Cancer Research ·Michael L. Maitland, Kristen Kasza, Theodore Karrison, (unknown), Laura Sit, Henry R. Black, Samir D. Undevia, Walter M. Stadler, W.J. Elliott, Mark J. Ratain	124
17	Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials 2008 ·Journal of Clinical Oncology ·Christopher K. Daugherty, Mark J. Ratain, Ezekiel J. Emanuel, Ann T. Farrell, Richard L. Schilsky	40
18	The Value Meal: How to Save $1,700 Per Month or More on Lapatinib 2007 ·Journal of Clinical Oncology ·Mark J. Ratain, Ezra E.W. Cohen	61
19	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·Journal of Clinical Oncology ·Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer	794
20	Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. 2003 ·PubMed ·Federico Innocenti, Mark J. Ratain	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact